Breast cancer in young women (≤35 years): Genomic aberrations detected by comparative genomic hybridization

International Journal of Cancer

Volumn 107, Issue 4, 2003, Pages 583-592

  Weber Mangal, Susanne ^a,b   Sinn, Hans Peter ^c   Popp, Susanne ^a,b   Klaes, Rüdiger ^a   Emig, Robert ^d   Bentz, Martin ^d   Mansmann, Ulrich ^a   Bastert, Gunther ^c   Bartram, Claus R ^a   Jauch, Anna ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d NONE

Author keywords

Comparative genomic hybridization; Early onset breast cancer; Gain of 8q; Loss of 8p

Indexed keywords

DNA;

ADULT; AGE; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CHROMOSOME 15Q; CHROMOSOME 16Q; CHROMOSOME 17P; CHROMOSOME 1P; CHROMOSOME 1Q; CHROMOSOME 20Q; CHROMOSOME 5P; CHROMOSOME 8Q; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE MUTATION; GENETIC GAIN; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; PRIORITY JOURNAL;

ADULT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHROMOSOME ABERRATIONS; DNA, NEOPLASM; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASMS, DUCTAL, LOBULAR, AND MEDULLARY; NUCLEIC ACID HYBRIDIZATION; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 0142021888     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11460     Document Type: Article

References (71)

1. Hankey BF, Miller B, Curtis R, Kosary C. Trends in breast cancer in younger women in contrast to older women. J Cancer Inst Monogr 1994;16:7-14.
2. Bonnier P, Romain S, Charpin C, Lejeune C, Tubiana N, Martin PM, Piana L. Age as a prognostic factor in breast cancer: relationship to pathologic and biologic features. Int J Cancer 1995;62:138-44.
3. Kothari AS, Fentiman IS. Breast cancer in young women. Int J Clin Pract 2002;56:184-7.
4. Pillers EM. Histological grade of breast cancer in younger women. Lancet 1992;339:1483.
5. Wenger CR, Beardslee S, Owens MA, Pounds G, Oldaker T, Vendely P, Pandian MR, Harrington D, Clark GM, McGuire WL. DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat 1993;28:9-20.
6. Walker RA, Lees E, Webb MB, Dearing SJ. Breast carcinomas occurring in young women (<35 years) are different. Br J Cancer 1996;74:1796-800.
7. Bertheau P, Steinberg SM, Cowan K, Merino MJ. Breast cancer in young women: clinicopathologic correlation. Semin Diagn Pathol 1999;16:248-56.
8. de la Rochefordiere A, Asselain B, Campana F, Scholl SM, Fenton J, Vilcoq JR, Durand JC, Pouillart P, Magdelenat H, Fourquet A. Age as prognostic factor in premenopausal breast carcinoma. Lancet 1993; 341:1039-43.
9. Chung M, Chang HR, Bland KI, Wanebo HJ. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer 1996;77:97-103.
10. Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, Thurlimann B, Rudenstam CM, Lindtner J, Crivellari D, Cortes-Funes H, Simoncini E, Werner ID, et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 2000;355:1869-74.
11. Xiong Q, Valero V, Kau V, Kau SW, Taylor S, Smith TL, Buzdar AU, Hortobagyi GN, Theriault RL. Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. Cancer 2001;92:2523-8.
12. Johnson SM, Shaw JA, Walker RA. Sporadic breast cancer in young women: prevalence of loss of heterozygosity at p53, BRCA1 and BRCA2. Int J Cancer 2002;98:205-9.
13. Ansquer Y, Gautier C, Fourquet A, Asselain B, Stoppa-Lyonnet D. Survival in early-onset BRCA1 breast-cancer patients. Institut Curie Breast Cancer Group. Lancet 1998;352:541.
14. Gentile M, Olsen K, Dufmats M, Wingren S. Frequent allelic losses at 11q24.1-q25 in young women with breast cancer: association with poor survival. Br J Cancer 1999a;80:843-9.
15. Gentile M, Wiman A, Thorstenson S, Loman N, Borg A, Wingren S. Deletion mapping of chromosome segment 11q24-q25, exhibiting extensive allelic loss in early onset breast cancer. Int J Cancer 2001; 92:208-13.
16. Querzoli P, Albonico G, di Iasio MG, Ferretti S, Rinaldi R, Cariello A, Pedriali M, Matteuzzi M, Maestri I, Nenci I. Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women. Breast Cancer Res Treat 2001;66:135-42.
17. Lai H, Lin L, Nadji M, Lai S, Trapido E, Meng L. Mutations in the p53 tumor suppressor gene and early onset breast cancer. Cancer Biol Ther 2002;1:31-6.
18. Gentile M, Bergman Jungestrom M, Olsen KE, Soderkvist P, Wingren S. p53 and survival in early onset breast cancer: analysis of gene mutations, loss of heterozygosity and protein accumulation. Eur J Cancer 1999b;35:1202-7.
19. Xing WR, Gilchrist KW, Harris CP, Samson W, Meisner LF. FISH detection of HER-2/neu oncogene amplification in early onset breast cancer. Breast Cancer Res Treat 1996;39:203-12.
20. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
21. Sobin LH, Wittekind C, eds. TNM classification of malignant tumors. 5th ed. New York: Wiley-Liss, 1997. 227 p.
22. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
23. du Manoir S, Speicher MR, Joos S, Schrock E, Popp S, Dohner H, Kovacs G, Robert-Nicoud M, Lichter P, Cremer T. Detection of complete and partial chromosome gains and losses by comparative genomic in situ hybridization. Hum Genet 1993;90:590-610.
24. Westfall PH, Young SS. On adjusting p-values for multiplicity. Biometrics 1993;49:941-945.
25. Courjal F, Theillet C. Comparative genomic hybridization analysis of breast tumors with predetermined profiles of DNA amplification. Cancer Res 1997;57:4368-77.
26. Loveday RL, Greenman J, Drew PJ, Monson JR, Kerin MJ. Genetic changes associated with telomerase activity in breast cancer. Int J Cancer 1999;84:516-20.
27. Roylance R, Gorman P, Harris W, Liebmann R, Barnes D, Hanby A, Sheer D. Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. Cancer Res 1999;59:1433-6.
28. Loveday RL, Greenman J, Simcox DL, Speirs V, Drew PJ, Monson JR, Kerin MJ. Genetic changes in breast cancer detected by comparative genomic hybridization. Int J Cancer 2000;86:494-500.
29. Seute A, Sinn HP, Schlenk RF, Emig R, Wallwiener D, Grischke EM, Hohaus S, Dohner H, Haas R, Bentz M. Clinical relevance of genomic aberrations in homogeneously treated high-risk stage II/III breast cancer patients. Int J Cancer 2001;93:80-4.
30. Zudaire I, Odero MD, Caballero C, Valenti C, Martinez-Penuela JM, Isola J, Calasanz MJ. Genomic imbalances detected by comparative genomic hybridization are prognostic markers in invasive ductal breast carcinomas. Histopathology 2002;40:547-55.
31. Gunther K, Merkelbach-Bruse S, Amo-Takyi BK, Handt S, Schroder W, Tietze L. Differences in genetic alterations between primary lobular and ductal breast cancers detected by comparative genomic hybridization. J Pathol 2001;193:40-7.
32. Kallioniemi A, Kallioniemi OP, Piper J, Tanner M, Stokke T, Chen L, Smith HS, Pinkel D, Gray JW, Waldman FM. Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc Natl Acad Sci USA 1994;91:2156-60.
33. Isola JJ, Kallioniemi OP, Chu LW, Fuqua SA, Hilsenbeck SG, Osborne CK, Waldman FM. Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol 1995;147:905-11.
34. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G. Kallioniemi OP, Trent JM, Meltzer PS. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997;277:965-8.
35. Collins C, Rommens JM, Kowbel D, Godfey T, Tanner M, Hwang S, Polikoff D, Nonet G, Cochran J, Myambo K, Jay KE, Froula J, et al. Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. Proc Natl Acad Sci USA 1998;95:8703-8.
36. Yokota T, Yoshimoto M, Akiyama F, Sakamoto G, Kasumi F, Nakamura Y, Emi M. Frequent multiplication of chromosomal region 8q24.1 associated with aggressive histologic types of breast cancers. Cancer Lett 1999a;139:7-13.
37. Rummukainen JK, Salminen T, Lundin J, Joensuu H, Isola JJ. Amplification of c-myc oncogene by chromogenic and fluorescence in situ hybridization in archival breast cancer tissue array samples. Lab Invest 2001;81:1545-51.
38. Sierra A, Castellsague X, Escobedo A, Moreno A, Drudis T, Fabra A. Synergistic cooperation between c-Myc and Bcl-2 in lymph node progression of T1 human breast carcinomas. Breast Cancer Res Treat 1999;54:39-45.
39. Hermsen MA, Baak JP, Meijer GA, Weiss JM, Walboomers JW, Snijders PJ, van Diest PJ. Genetic analysis of 53 lymph node-negative breast carcinomas by CGH and relation to clinical, pathological, morphometric, and DNA cytometric prognostic factors. J Pathol 1998; 186:356-62.
40. Richard F, Pacyna-Gengelbach M, Schluns K, Fleige B, Winzer KJ, Szymas J, Dietel M, Petersen I, Schwendel A. Patterns of chromosomal imbalances in invasive breast cancer. Int J Cancer 2000;89: 305-10.
41. Wai DH, Schaefer KL, Schramm A, Korsching E, Van Valen F, Ozaki T, Boecker W, Schweigerer L, Dockhorn-Dworniczak B, Poremba C. Expression analysis of pediatric solid tumor cell lines using oligonucleotide microarrays. Int J Oncol 2002;20:441-51.
42. Dawkins HJ, Robbins PD, Smith KL, Sarna M, Harvey JM, Sterrett GF, Papadimitriou JM. What's new in breast cancer? Molecular perspectives of cancer development and the role of the oncogene c-erbB-2 in prognosis and disease. Pathol Res Pract 1993;189:1233-52.
43. Bärlund M, Monni O, Kononen J, Cornelison R, Torhorst J, Sauter G, Kallioniemi OP, Kallioniemi A. Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. Cancer Res 2000; 60:5340-4.
44. Wu GJ, Sinclair CS, Paape J, Ingle JN, Roche PC, James CD, Couch FJ. 17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGma1B genes. Cancer Res 2000;60:5371-5.
45. Tanner MM, Tirkkonen M, Kallioniemi A, Holli K, Collins C, Kowbel D, Gray JW, Kallioniemi OP, Isola J. Amplification of chromosomal region 20q13 in invasive breast cancer: prognostic implications. Clin Cancer Res 1995;1:1455-61.
46. Tanner MM, Tirkkonen M, Kallioniemi A, Isola J, Kuukasjarvi T, Collins C, Kowbel D, Guan XY, Trent J, Gray JW, Meltzer P, Kallioniemi OP. Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer. Cancer Res 1996;56:3441-5.
47. Courjal F, Cuny M, Rodriguez C, Louason G, Speiser P, Katsaros D, Tanner MM, Zeillinger R, Theillet C. DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours. Br J Cancer 1996;74:1984-9.
48. Hyman E, Kauraniemi P, Hautaniemi S, Wolf M, Mousses S, Rozenblum E, Ringner M, Sauter G, Monni O, Elkahloun A, Kallioniemi OP, Kallioniemi A. Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res 2002;62:6240-5.
49. Poremba C, Heine B, Diallo R, Heinecke A, Wai D, Schaefer KL, Braun Y, Schuck A, Lanvers C, Bankfalvi A, Kneif S, Torhorst J, et al. Telomerase as a prognostic marker in breast cancer: high-through-put tissue microarray analysis of hTERT and hTR. J Pathol 2002;198: 181-9.
50. Ma YY, Wei SJ, Lin YC, Lung JC, Chang TC, Whang-Peng J, Liu JM, Yang DM, Yang WK, Shen CY. PIK3CA as an oncogene in cervical cancer. Oncogene 2000;19:2739-44.
51. Zhang A, Maner S, Betz R, Angstrom T, Stendahl U, Bergman F, Zetterberg A, Wallin KL. Genetic alterations in cervical carcinomas: frequent low-level amplifications of oncogenes are associated with human papillomavirus infection. Int J Cancer 2002;101:427-33.
52. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21:99-102.
53. Daigo Y, Chin SF, Gorringe KL, Bobrow LG, Ponder BA, Pharoah PD, Caldas C. Degenerate oligonucleotide primed-polymerase chain reaction-based array comparative genomic hybridization for extensive amplicon profiling of breast cancers: a new approach for the molecular analysis of paraffin-embedded cancer tissue. Am J Pathol 2001; 158:1623-31.
54. Knuutila S, Aalto Y, Autio K, Bjorkqvist AM, El-Rifai W, Hemmer S, Huhta T, Kettunen E, Kiuru-Kuhlefelt S, Larramendy ML, Lushnikova T, Monni O, et al. DNA copy number losses in human neoplasms. Am J Pathol 1999;155:683-94.
55. Qin LX. Chromosomal aberrations related to metastasis of human solid tumors. World J Gastroenterol 2002;8:769-76.
56. Wang JC, Radford DM, Holt MS, Helms C, Goate A, Brandt W, Parik M, Phillips NJ, DeSchryver K, Schuh ME, Fair KL, Ritter JH, et al. Sequence-ready contig for the 1.4-cM ductal carcinoma in situ loss of heterozygosity region on chromosome 8p22-p23. Genomics 1999;60: 1-11.
57. Yokota T, Yoshimoto M, Akiyama F, Sakamoto G, Kasumi F, Nakamura Y, Emi M. Localization of a tumor suppressor gene associated with the progression of human breast carcinoma within a 1-cM interval of 8p22-p23.1. Cancer 1999b;85:447-52.
58. Yuan BZ, Miller MJ, Keck CL, Zimonjic DB, Thorgeirsson SS, Popescu NC. Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res 1998;58:2196-9.
59. Ishii H, Baffa R, Numata SI, Murakumo Y, Rattan S, Inoue H, Mori M, Fidanza V, Alder H, Croce CM. The FEZ1 gene at chromosome 8p22 encodes a leucine-zipper protein, and its expression is altered in multiple human tumors. Proc Natl Acad Sci USA 1999;96:3928-33.
60. Liao C, Zhao M, Song H, Uchida K, Yokoyama KK, Li T. Identification of the gene for a novel liver-related putative tumor suppressor at a high-frequency loss of heterozygosity region of chromosome 8p23 in human hepatocellular carcinoma. Hepatology 2000;32:721-7.
61. Van Hul W, Wuyts W, Hendrickx J, Speleman F, Wauters J, De Boulle K, Van Roy N, Bossuyt P, Willems PJ. Identification of a third EXT-like gene (EXTL3) belonging to the EXT gene family. Genomics 1998;47:230-7.
62. Thor AD, Eng C, Devries S, Paterakos M, Watkin WG, Edgerton S, Moore DH 2nd, Etzell J, Waldman FM. Invasive micropapillary carcinoma of the breast is associated with chromosome 8 abnormalities detected by comparative genomic hybridization. Hum Pathol 2002;33:628-31.
63. Seitz S, Wassmuth P, Fischer J, Nothnagel A, Jandrig B, Schlag PM, Scherneck S. Mutation analysis and mRNA expression of trail-receptors in human breast cancer. Int J Cancer 2002;102:117-28.
64. Kerangueven F, Essioux L, Dib A, Noguchi T, Allione F, Geneix J, Longy M, Lidereau R, Eisinger F, Pebusque MJ, Jacquemier J, Bonaiti-Pellié C, et al. Loss of heterozygosity and linkage analysis in breast carcinoma: indication for a putative third susceptibility gene on the short arm of chromosome 8. Oncogene 1995;10: 1023-6.
65. Seitz S, Rohde K, Bender E, Nothnagel A, Kolble K, Schlag PM, Scherneck S. Strong indication for a breast cancer susceptibility gene on chromosome 8p12-p22: linkage analysis in German breast cancer families. Oncogene 1997;14:741-3.
66. Yaremko ML, Kutza C, Lyzak J, Mick R, Recant WM, Westbrook CA. Loss of heterozygosity from the short arm of chromosome 8 is associated with invasive behavior in breast cancer. Genes Chromosomes Cancer 1996;16:189-95.
67. Sigbjörnsdottir BI, Ragnarsson G, Agnarsson BA, Huiping C, Barkardottir RB, Egilsson V, Ingvarsson S. Chromosome 8p alterations in sporadic and BRCA2 999del5 linked breast cancer. J Med Genet 2000;37:342-7.
68. Hansen LL, Yilmaz M, Overgaard J, Andersen J, Kruse TA. Allelic loss of 16q23.2-24.2 is an independent marker of good prognosis in primary breast cancer. Cancer Res 1998;58:2166-9.
69. Filippova GN, Lindblom A, Meincke LJ, Klenova EM, Neiman PE, Collins SJ, Doggett NA, Lobanenkov VV. A widely expressed transcription factor with multiple DNA sequence specificity, CTCF, is localized at chromosome segment 16q22.1 within one of the smallest regions of overlap for common deletions in breast and prostate cancers. Genes Chromosomes Cancer 1998;22:26-36.
70. Etzell JE, Devries S, Chew K, Florendo C, Molinaro A, Ljung BM, Waldman FM. Loss of chromosome 16q in lobular carcinoma in situ. Hum Pathol 2001;32:292-6.
71. Sato M, Mori Y, Sakurada A, Fujimura S, Horii A. The H-cadherin (CDH13) gene is inactivated in human lung cancer. Hum Genet 1998;103:96-101.